Co-op: In-Process Analytics

Advanced cell-based therapy booming the success for healthcare sector. Mar 24, 2026, 10:00 ET Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /CNW/ - USANewsGroup.com - The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. But every cell-based therapy - no matter how revolutionary the science - begins with the same foundational requirement: a reliable, standardized bank of cells to work from. Without that cellular starting material, there is no consistency, no scalability, and no path from laboratory discovery to therapeutic development. A Master Cell Bank (MCB) is the process of taking a single genetically engineered cell and cloning it into tens of millions of identical copies under GMP-compliant conditions. It's the foundational infrastructure that ensures every subsequent step in therapy development works from the same characterized, quality-controlled source. It's not the therapy itself - it's the prerequisite that makes therapy development possible. That distinction matters, because the companies advancing cell therapies right now are each navigating their own version of the journey from cellular science to clinical reality. Prime Medicine (NASDAQ: PRME) is developing prime editing - a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing off-target risks that have haunted earlier CRISPR approaches. The precision is remarkable, but the path from edited cell to approved therapy is measured in years of development, trials, and manufacturing scale-up. Madrigal Pharmaceuticals (NASDAQ: MDGL) presented two-year data showing its therapy, Rezdiffra, significantly improved liver stiffness and fibrosis biomarkers in patients with compensated MASH cirrhosis - demonstrating that biological interventions can deliver sustained, measurable reversal of chronic organ damage. Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, the first approved tumor-infiltrating lymphocyte therapy for advanced melanoma. It's a landmark, but each treatment must be custom-manufactured from the individual patient's own tumor tissue - underscoring how critical scalable cellular infrastructure is to the future of the field. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and multiple FDA designations, requiring precise protein engineering to cross the blood-brain barrier. Each of these programs illustrates the same truth: the distance between discovering a biological mechanism and delivering it to patients is defined by the quality of the cellular and manufacturing foundation underneath it. Avaí Bio (OTCQB: AVAI) recently announced the start of a key early-stage milestone alongside joint venture partner Austrianova: creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein. The MCB process clones a single engineered cell into tens of millions of identical copies, establishing the standardized cellular starting material from which all future working cell banks and therapy development for the Klothonova program will proceed. Prof. Walter H. Gunzburg, Chairman of Austrianova, said: "MCBs are a prerequisite for the production of Cell-in-a-Box(R) encapsulated cell products. They provide the foundation for sustainable production and ensure they meet the highest quality standards." The α-Klotho protein at the center of the Klothonova program is one of the most studied protective molecules in aging science. Peer-reviewed research links higher Klotho levels to reduced risk of Alzheimer's, cardiovascular disease, and certain cancers, while natural levels decline by approximately 50% after age 40. The addressable markets span Alzheimer's ($32.8 billion by 2033), cardiovascular disease (the world's leading cause of death), and kidney disease (850 million affected globally). Avaí Bio's dual-program approach also targets diabetes through the Insulinova platform, which, like Klothonova, leverages Austrianova's Cell-in-a-Box(R) encapsulation technology - a delivery system that protects therapeutic cells inside a biocompatible shell, allowing continuous protein secretion without immune rejection. The technology is backed by over 50 peer-reviewed publications. Every cell therapy begins with a single cell. The question is whether that cell has been properly characterized, cloned, and banked under the conditions required to support everything that comes after it. Avaí Bio (OTCQB: AVAI) just answered that question for its α-Klotho program - in a market heading toward $45 billion where the cellular foundation is what separates science from development. Read this and more news for Avaí Bio at: USANewsGroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avaí Bio, Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Avaí Bio, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avaí Bio, Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avaí Bio, Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Prime Medicine has reported full-year 2025 financial results, ending the year with $191.4 million in cash, providing a financial runway into 2027. The company posted a net loss of $201.1 million whilst focusing resources on its in vivo liver franchise. The biotech is advancing regulatory filings for Wilson Disease and Alpha-1 Antitrypsin Deficiency programmes, with IND or CTA submissions planned for H1 2026 and mid-2026 respectively. Initial clinical data for both indications is expected in 2027. Prime Medicine is also pursuing accelerated FDA approval for PM359, its chronic granulomatous disease candidate, following positive Phase 1/2 data published in the New England Journal of Medicine. The company has deprioritised its CGD programme to focus on high-priority clinical milestones whilst continuing its CAR-T partnership with Bristol Myers Squibb.